Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 54.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 103,936 shares of the biotechnology company’s stock after purchasing an additional 36,714 shares during the quarter. Franklin Resources Inc. owned 0.38% of Arcturus Therapeutics worth $2,412,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ARCT. Sumitomo Mitsui Trust Group Inc. lifted its position in Arcturus Therapeutics by 45.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Arcturus Therapeutics by 6.9% in the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock valued at $48,765,000 after buying an additional 136,074 shares during the period. Millennium Management LLC boosted its stake in Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after buying an additional 396,505 shares in the last quarter. Geode Capital Management LLC raised its position in Arcturus Therapeutics by 1.1% in the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after acquiring an additional 5,789 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Arcturus Therapeutics by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after acquiring an additional 3,224 shares during the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Tuesday, December 17th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $66.75.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.30% of the company’s stock.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $16.93 on Friday. The company has a market cap of $458.58 million, a P/E ratio of -7.63 and a beta of 2.62. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The firm’s 50 day simple moving average is $17.98 and its 200-day simple moving average is $21.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the prior year, the company earned ($0.61) earnings per share. On average, analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.